Rational for statin use in psoriatic patients

Archives of Dermatological Research

Volumn 305, Issue 6, 2013, Pages 467-472

  Mosiewicz, Jerzy ^a   Pietrzak, Aldona ^a   Chodorowska, Grazyna ^a   Trojnar, Marcin ^a   Szepietowski, Jacek ^b   Reich, Kristian ^c   Rizzo, Manfredi ^d,e  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^b WROCLAW MEDICAL UNIVERSITY   (Poland)

^c DERMATOLOGIKUM HAMBURG   (Germany)

^d UNIVERSITY OF PALERMO   (Italy)

^e Euro Mediterranean Institute of Science and Technology   (Italy)

Author keywords

Atorvastatin; Cholesterol; Fluvastatin; Psoriasis; Simvastatin; Statins

Indexed keywords

ANTIMALARIAL AGENT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETAMETHASONE; CALCIUM ANTAGONIST; CHEMOKINE RECEPTOR CCR6; CORTICOSTEROID; CYCLOSPORIN; CYTOCHROME P450 3A4; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERCELLULAR ADHESION MOLECULE 1; INTERFERON; KERATOLYTIC AGENT; LITHIUM; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; MEVINOLIN; NEUROLEPTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PITAVASTATIN; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TETRACYCLINE; UNINDEXED DRUG;

ANTIINFLAMMATORY ACTIVITY; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR RISK; CD4+ T LYMPHOCYTE; CHOLESTEROL SYNTHESIS; CYTOKINE PRODUCTION; DERMATOMYOSITIS; DISEASE ASSOCIATION; DISEASE EXACERBATION; DRUG EFFICACY; DRUG METABOLISM; DRUG USE; DRUG WITHDRAWAL; ENZYME INHIBITION; HUMAN; IMMUNOMODULATION; LEUKOCYTE ADHERENCE; LICHEN PLANUS; LIPID METABOLISM; MYOPATHY; NEUTROPHIL CHEMOTAXIS; PEMPHIGOID; POLYMYOSITIS; PRIORITY JOURNAL; PSORIASIS; PSORIASIS AREA AND SEVERITY INDEX; PSORIASIS VULGARIS; REVIEW; RHABDOMYOLYSIS; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT DURATION;

ANIMALS; DERMATOLOGIC AGENTS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PSORIASIS; SKIN; TREATMENT OUTCOME;

EID: 84880916428     PISSN: 03403696     EISSN: 1432069X     Source Type: Journal    
DOI: 10.1007/s00403-013-1374-1     Document Type: Review

References (47)

1. Aronson PJ, Friedman DB (1992) Pharmacologic doses of lovastatin do not predictably affect the course of psoriasis. Arch Dermatol 128(1):124
2. Beller GA (2008) What can be learned from the COURAGE trial? J Nucl Cardiol 15:1-2
3. Bellosta S, Paoletti R, Corsini A (2004) Safety of statins: focus on clinical pharmacokinetics and drug interactions. Circulation 109(23 Suppl 1):III50-III57
4. Boehncke WH, Boehncke S, Schön MP (2010) Managing comorbid disease in patients with psoriasis. BMJ 340:b5666
5. Brauchli YB, Jick SS, Meier CR (2011) Statin use and risk of first-time psoriasis diagnosis. J Am Acad Dermatol 65:77-83
6. Charo IF, Ransohoff RM (2006) The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med 354:610-621
7. Cozzani E, Scaparro M, Parodi A (2009) A case of psoriasis worsened by atorvastatin. J Dermatol Case Rep 3:60-61
8. Duncan RE, El-Sohemy A, Archer MC (2005) Statins and cancer development. Can Epidemiol Biom Prev 14(8):1897-1898
9. Egesi A, Sun G, Khachemoune A, Rashid RM (2010) Statins in skin: research and rediscovery, from psoriasis to sclerosis. J Drugs Dermatol 9(8):921-927
10. Faghihi T, Radfar M, Mehrabian Z, Ehsani AH, Rezaei Hemami M (2011) Atorvastatin for the treatment of plaque-type psoriasis. Pharmacotherapy 31:1045-1050
11. Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB (2006) Risk of myocardial infarction in patients with psoriasis. JAMA 296:1735-1741
12. Ghazizadeh R, Tosa M, Ghazizadeh M (2011) Clinical improvement in psoriasis with treatment of associated hyperlipidemia. Am J Med Sci 341(5):394-398
13. Gottlieb AB, Dann F (2009) Comorbidities in patients with psoriasis. Am J Med 122:1150-1159
14. Goldminz AM, Au SC, Kim N, Gottlieb AB, Lizzul PF (2012) NF-κB: an essential transcription factor in psoriasis. J Dermatol Sci 69(2):89-94
15. Greenwood J, Steinman L, Zamvil SS (2006) Statin therapy and autoimmune disease: from protein prenylation to immunomodulation. Nat Rev Immunol 6:358-370
16. Gressier L, Pruvost-Balland C, Dubertret L, Viguier M (2009) Atorvastatin-induced drug reaction with eosinophilia and systemic symptoms (DRESS). Ann Dermatol Venereol 136:50-53
17. Grip O, Janciauskiene S, Bredberg A (2008) Use of atorvastatin as an anti-inflammatory treatment in Crohn's disease. Br J Pharmacol 155:1085-1092
18. Hilgendorff A, Muth H, Parviz B, Staubitz A, Haberbosch W, Tillmanns W et al (2003) Statins differ in their ability to block NF-kappaB activation in human blood monocytes. Int J Clin Pharmacol Ther 41(2003):397-401
19. Jacobi TC, Highet A (2003) A clinical dilemma while treating hypercholesterolaemia in psoriasis. Br J Dermatol 149:1305-1306
20. Jowkar F, Namazi MR (2010) Statins in dermatology. Int J Dermatol 49(11):1235-1243
21. Kim N, Thrash B, Menter A (2010) Comorbidities in psoriasis patients. Semin Cutan Med Surg 29:10-15
22. Kim TG, Byamba D, Wu WH, Lee MG (2011) Statins inhibit chemotactic interaction between CCL20 and CCR6 in vitro: possible relevance to psoriasis treatment. Exp Dermatol 20(10):855-857
23. Kwatra SG (2011) Statins differ significantly in their anti-inflammatory activity. J Am Acad Dermatol 65(6):1229 Author reply 1229-30
24. Lin SL, Chien CW, Han CL, Chen ES, Kao SH, Chen YJ, Liao F (2010) Temporal proteomics profiling of lipid rafts in CCR6-activated T cells reveals the integration of actin cytoskeleton dynamics. J Proteome Res 9:283-297
25. Montanaro S, Lhiaubet-Vallet V, Iesce MI, Previtera L, Miranda MA (2009) A mechanistic study on the phototoxicity of atorvastatin: singlet oxygen generation by a phenanthrene-like photoproduct. Chem Res Toxicol 22:173-178
26. Naldi L (2004) Epidemiology of psoriasis. Curr Drug Targets Inflamm Allergy 3:121-128
27. Namazi MR (2004) Statins: novel additions to the dermatologic arsenal? Exp Dermatol 13(6):337-339
28. Naseri M, Hadipour A, Sepaskhah M, Namazi MR (2010) The remarkable beneficial effect of adding oral simvastatin to topical betamethasone for treatment of psoriasis: a double-blind, randomized, placebo-controlled study. Niger J Med 19:58-61
29. Noël B (2007) Lupus erythematosus and other autoimmune diseases related to statin therapy: a systematic review. J Eur Acad Dermatol Venereol 21(1):17-24
30. Prospective Studies Collaboration, Lewington S, Whitlock G, Clarke R, Sherliker P, Emberson J, Halsey J et al (2007) Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet 370(9602):1829-1839
31. Qi XF, Kim DH, Yoon YS, Li JH, Jin D, Teng YC et al (2009) Fluvastatin inhibits expression of the chemokine MDC/CCL22 induced by interferon-γ in HaCaT cells, a human keratinocyte cell line. Br J Pharmacol 157:1441-1450
32. Raychaudhuri SP, Farber EM (2001) The prevalence of psoriasis in the world. J Eur Acad Dermatol Venereol 15:16-17
33. Reich K, Langley RG, Lebwohl M, Szapary P, Guzzo C, Yeilding N et al (2011) Cardiovascular safety of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studies. Br J Dermatol 164(4):862-872
34. Reiter M, Wirth S, Pourazim A, Baghestanian M, Minar E, Bucek RA (2005) Statin therapy has no significant effect on skin tissue cholesterol: results from a prospective randomized trial. Clin Chem 51:252-254
35. Rizzo M, Spinas GA, Rini GB, Berneis K (2010) Is diabetes the cost to pay for a greater cardiovascular prevention? Int J Cardiol 144(2):309-310
36. Schachter M (2005) Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam Clin Pharmacol 19:117-125
37. Schmutz JL, Barbaud A, Tréchot P (2008) Effets secondaires cutanés des bstatines. Ann Dermatol Venereol 135:253-254
38. Shirinsky IV, Shirinsky VS (2007) Efficacy of simvastatin in plaque psoriasis: a pilot study. J Am Acad Dermatol 57(3):529-531
39. Späh F (2008) Inflammation in atherosclerosis and psoriasis: common pathogenic mechanisms and the potential for an integrated treatment approach. Br J Dermatol 159(Suppl 2):10-17
40. Tablazon IL, Al-Dabagh A, Davis SA, Feldman SR (2013) Risk of cardiovascular disorders in psoriasis patients: current and future. Am J Clin Dermatol 14(1):1-7
41. Thompson PD, Clarkson P, Karas RH (2003) Statin-associated myopathy. JAMA 289:1681-1690
42. Tapon N, Hall A (1997) Rho, Rac and Cdc42 GTPases regulate the organization of the actin cytoskeleton. Curr Opin Cell Biol 9(1):86-92
43. Taylor F, Ward K, Moore TH, Burke M, Davey Smith G, Casas JP et al (2011) Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 1:CD004816
44. Vasiuk IuA, Perlamutrov IuN, Shkol'nik MN, Shkol'nik EL (2010) Possibilities of atorvastatin in complex management of extensive psoriasis in patients with arterial hypertension. Kardiologiia 50(3):37-46
45. Waehre T, Damås JK, Gullestad L, Holm AM, Pedersen TR, Arnesen KE et al (2003) Hydroxymethylglutaryl coenzyme a reductase inhibitors down-regulate chemokines and chemokine receptors in patients with coronary artery disease. J Am Coll Cardiol 41:1460-1467
46. Weitz-Schmidt G, Welzenbach K, Brinkmann V, Kamata T, Kallen J, Bruns C et al (2001) Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med 7:687-692
47. Yamamoto M, Ikeda M, Kodama H, Sano S (2008) Transition of psoriasiform drug eruption to psoriasis de novo evidenced by histopathology. J Dermatol 35:732-736